---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-284964"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2021-09-28T23:59:59+00:00"
generated_at: "2026-06-29T01:02:32.336069+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Alector appoints Elizabeth Garofalo, M.D. to Board of Directors

## Summary
- Dr. Garofalo appointed as Class II director with term expiring at 2023 annual meeting; effective Sept. 23, 2021.
- Over 25 years of neurology drug development experience; formerly SVP and Global Head of Clinical Development at Novartis.
- Received initial option grant of 33,235 shares (four-year vest) and annual cash retainer of $40,000.
- Currently serves on boards of Acadia Pharmaceuticals, Exicure Inc., and Xenon Pharmaceuticals.

## SEC filing metadata
- accession: 0001193125-21-284964
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2021-09-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/0001193125-21-284964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/d234235d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-284964
- JSON: https://secwatch.observer/filing/0001193125-21-284964.json
- Plain text: https://secwatch.observer/filing/0001193125-21-284964.txt

## Key facts
- Executive change
  Elizabeth A. Garofalo was appointed as Class II director at Alector, Inc..
  - Action: appointed
  - Role: Class II director
  source text: On September 23, 2021, Elizabeth A. Garofalo, M.D. was appointed to the Board of Directors (the “Board”) of Alector, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/0001193125-21-284964-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.